BriaCell to Present at Biotech Showcase™ 2020 in San Francisco
December 17 2019 - 6:30AM
BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapies for advanced
breast cancer, announces its attendance and presentation scheduled
at Biotech Showcase™ 2020, to be held January 13–15, during the
most important week in healthcare at the Hilton San Francisco Union
Square. If you are an institutional or private investor, and would
like to attend BriaCell’s presentation, please register to attend
the conference
here. Once registered, you will be
prompted to log into the conference website to request a one-on-one
meeting with BriaCell.
Dr. Bill Williams, BriaCell’s President &
CEO, will be presenting BriaCell’s unique and effective
immunotherapy approach at Biotech Showcase™ as follows:
Date: Wednesday, January 15,
2020Time: 10:00 a.m. PST (1:00 p.m.
EST)Location: Hilton San Francisco Union Square
Hotel, 333 O'Farrell Street, San FranciscoTrack:
Yosemite C (Ballroom Level)
Following the presentation, a copy will be posted
on https://briacell.com/investor-relations/presentations/.
"We are very excited to be one of the leading
biotech innovators presenting at Biotech Showcase™," stated Dr.
Bill Williams. “Our novel immunotherapy, Bria-IMT™, has shown
promising early results in combination with checkpoint inhibitors
including pembrolizumab (KEYTRUDA®; manufactured by Merck &
Co., Inc.), and more recently, Incyte’s INCMGA00012, in advanced
breast cancer. We look forward to continuing our efforts to bring
hope to this most vulnerable patient population."
About Biotech Showcase™
Biotech Showcase™ is an investor and networking
conference devoted to providing private and public biotechnology
and life sciences companies with an opportunity to present to, and
meet with, investors and pharmaceutical executives in one place.
Investors and biopharmaceutical executives from around the world
gather in San Francisco during this bellwether week which sets the
tone for the coming year. Now in its 12th year, this
well-established, highly respected conference features multiple
tracks of presenting companies, plenary sessions, workshops,
networking, and an opportunity to schedule one-to-one meetings.
Biotech Showcase™ is produced by Demy-Colton and EBD Group. Both
organizations have a long history of producing high-quality
programs that support the biotechnology and broader life sciences
industry.
For additional information on Biotech Showcase™
2020, please visit:
https://ebdgroup.knect365.com/biotech-showcase/.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and safe approaches for
the management of cancer.
BriaCell is conducting a Phase I/IIa clinical
trial of Bria-IMT™, BriaCell’s lead candidate, in a Combination
Study with immune checkpoint inhibitors such as the Incyte drugs
INCMGA00012 (an anti-PD-1 antibody similar to pembrolizumab
[KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)]) and
epacadostat, an orally bioavailable small-molecule inhibitor of
indoleamine 2,3-dioxygenase 1 (IDO1). The combination study is
listed in ClinicalTrials.gov as NCT03328026.
BriaCell currently has a non-exclusive clinical
trial collaboration with Incyte Corporation to evaluate the effects
of combinations of novel clinical candidates. Under the agreement,
Incyte and BriaCell will be evaluating novel combinations of
compounds from Incyte’s development portfolio with BriaCell’s drug
candidates in advanced breast cancer patients.
BriaCell is also developing Bria-OTS™, an
off-the-shelf personalized immunotherapy, for advanced breast
cancer. Bria-OTS™ immunotherapy treatments are personalized to
match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 99 percent of the
patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while
eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024